Converge Bio
Generative AI Platform for Biological Engineering
Startup Seed Health Tech & Life Sciences Est. 2024
🌐 WebsiteLinkedIn
Total Raised
$5.5M
Seed
Last Round
$5.5M
2 rounds
Investors
1
1 public
Team
4
11-50 employees
Confidence
72/100
News
2
articles
About
Converge Bio is aiming is revolutionize biological R&D by creating a Generative AI platform for DNA, RNA, and protein sequences.
Classification
Sector
Health Tech & Life SciencesPharma & Medical Biotechnology
Core Technology
Artificial IntelligenceGenerative AI
Target Customer
Healthcare & Life SciencesLife SciencesBiotechnologyPharmaceuticals
Business Model
B2B
Tags
pharmaceuticalsbiotechnologymolecular-biologyproteins
Funding & Events
Nov 2024
Seed $5.5M
TLV Partners
Mar 2024
Seed Undisclosed
TLV Partners (Lead)
News (2)
Nov 20, 2024 · www.calcalistech.com
growth-positive
Converge Bio raises $5.5M in Seed funding to speed up drug discovery and development with GenAI | CTech
InvestmentPartners
Nov 20, 2024 · www.prnewswire.com
growth-positive
/PRNewswire/ -- Converge Bio, a generative AI platform for accelerated drug discovery and development, today announced it has raised $5.5 million in seed...
InvestmentPartners
Details
Product Stage
R&D
Employees
11-50
Exact Count
28
District
Center District
Founded
2024
Registrar
516949781
Locations
Daniel Frisch St, Tel Aviv-Yafo, Israel
Links
Website
converge-bio.com
LinkedIn
Profile
Admin
Last Update
Mar 24, 2025
Verified by
Matan Eblagon
Missing
sector, description, video or image, markets, not claimed
Team (4)
Dov Gertz
Co-founder & CEO
Oded Kalev
Co-founder & CTO
Founder
Iddo Weiner
CSO
Eli Weber
Scientific Partnerships & Strategy
Internal
Created by
Maor Perlov (maor.perlov@sncentral.org)
Created
2024-05-02T00:00:00.000Z
Last editor
Matan Eblagon (matane@sncentral.org)
Finder · Converge Bio · 2026